Prescient Therapeutics (ASX:PTX) raised around AU$4.8 million via its share purchase plan and around AU$1.2 million in the shortfall placement, according to a Wednesday Australian bourse filing.

The issue price under the share purchase plan and the placement was AU$0.065 apiece. Around 18.5 million new shares are expected to be issued under the placement.

The proceeds will provide additional funding for the continued development of its PTX-100 treatment candidate beyond the first dose optimization committee review.

Its shares fell 2% in recent trading on Wednesday.